镓-68标记DOTA-TOC正电子发射断层显像在儿童神经母细胞瘤显像中优于氟-18标记FDOPA和氟-18标记FDG正电子发射断层显像:一项前瞻性研究
该前瞻性研究纳入15例组织学确诊的神经母细胞瘤患者,同期行镓-68标记DOTA-TOC、氟-18标记FDOPA和氟-18标记FDG三种正电子发射断层显像。基于病灶分析,镓-68标记DOTA-TOC的检出率98.0%高于氟-18标记FDOPA的63.5%和氟-18标记FDG的60.1%(P<0.001),最大标准化摄取值也以镓-68标记DOTA-TOC最高。
要点
- 基于患者分析,氟-18标记FDG漏诊2例活动性疾病,检出率86.7%(13/15),镓-68标记DOTA-TOC和氟-18标记FDOPA均检出全部15例(100%)。
- 基于203个病灶分析,镓-68标记DOTA-TOC检出199个(98.0%),高于氟-18标记FDOPA的129个(63.5%)和氟-18标记FDG的122个(60.1%)(P<0.001)。
- 最大标准化摄取值以镓-68标记DOTA-TOC最高(5.5±4.0),其次为氟-18标记FDG(1.8±1.4)和氟-18标记FDOPA(0.6±0.5)(P<0.001)。
核心结论
- 神经母细胞瘤生长抑素受体富集,使镓-68标记DOTA-TOC正电子发射断层显像成为与氟-18标记FDOPA和氟-18标记FDG相比的高效检测工具。
- 多模态影像方法可增强疾病评估并指导个体化治疗策略,可能有助于放射性配体治疗。
研究设计与样本
- 前瞻性研究,于2021年9月至2024年9月招募组织学确诊的神经母细胞瘤患者。
- 所有参与者均接受三种放射性示踪剂的正电子发射断层显像,共15例患者(平均年龄6.1±3.4岁;女性6例,男性9例),以M期(13/15例)和高危(14/15例)为主。
- 骨病灶采用SIOPEN系统评估,正电子发射断层显像所见经多学科肿瘤委员会讨论并随访影像确认为真性病灶。
- 检出率比较采用Cochran Q检验,最大标准化摄取值采用重复测量方差分析及事后两两比较。
主要发现
- 基于患者分析,氟-18标记FDG正电子发射断层显像未检出2例患者的活动性疾病,检出率86.7%(13/15),而镓-68标记DOTA-TOC和氟-18标记FDOPA均检出全部患者(15/15,100%)。
- 基于病灶分析共识别203个病灶,镓-68标记DOTA-TOC检出199/203(98.0%),高于氟-18标记FDOPA的129/203(63.5%)和氟-18标记FDG的122/203(60.1%)(P<0.001)。
- 最大标准化摄取值以镓-68标记DOTA-TOC最高(5.5±4.0),其次为氟-18标记FDG(1.8±1.4)和氟-18标记FDOPA(0.6±0.5)(P<0.001)。
- 基于器官分析,镓-68标记DOTA-TOC在淋巴结转移(55/57,96.5%)、软组织转移(43/43,100%)、骨和骨髓转移(89/89,100%)中检出率更高。
- 镓-68标记DOTA-TOC正电子发射断层显像/计算机断层显像在原发灶和转移灶中的最大标准化摄取值普遍更高(均P<0.001),但肝脏除外;多数病灶(170/203,83.7%)Krenning评分≥2。
关键数值与推荐
- 基于患者检出率:镓-68标记DOTA-TOC 15/15(100%)vs 氟-18标记FDOPA 15/15(100%)vs 氟-18标记FDG 13/15(86.7%)。
- 基于病灶检出率:镓-68标记DOTA-TOC 199/203(98.0%)vs 氟-18标记FDOPA 129/203(63.5%)vs 氟-18标记FDG 122/203(60.1%)(P<0.001)。
- 最大标准化摄取值:镓-68标记DOTA-TOC 5.5±4.0 vs 氟-18标记FDG 1.8±1.4 vs 氟-18标记FDOPA 0.6±0.5(P<0.001)。
- 器官特异性检出率:淋巴结55/57(96.5%)、软组织43/43(100%)、骨和骨髓89/89(100%)。
- Krenning评分≥2的病灶为170/203(83.7%)。
临床怎么用
- 原文结论认为镓-68标记DOTA-TOC正电子发射断层显像与氟-18标记FDOPA和氟-18标记FDG相比是高效的检测工具。
- 原文结论提出多模态影像方法可增强疾病评估并指导个体化治疗策略,可能有助于放射性配体治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Neuroblastoma is a heterogeneous pediatric malignancy with variable imaging characteristics. Neuroblastoma tumors express SSTR receptors, but the role of [68Ga]Ga-DOTA-TOC in neuroblastoma remains unclear. This study aimed to compare the diagnostic accuracy of [68Ga]Ga-DOTA-TOC PET against [18F]FDOPA PET and [18F]FDG PET in neuroblastoma. METHODS: Patients with histologically confirmed neuroblastoma were prospectively recruited between September 2021 and September 2024. All participants underwent PET imaging using three radiotracers. Each modality was assessed for lesion detectability. Bone lesions were evaluated using the SIOPEN system. PET findings were interpreted as true lesions following multidisciplinary tumor board discussions and confirmed with follow-up imaging. Detectability across modalities was compared using Cochran's Q test, while maximal standardized uptake values (SUVmax) were analyzed using repeated measures ANOVA and post hoc pairwise comparisons. RESULTS: Fifteen patients (mean age 6.1 ± 3.4; 6 females and 9 males) underwent paired PET imaging using three different radiotracers, predominantly stage M (13/15 patients) and high risk (14/15 patients). In patient-based analysis, [18F]FDG PET failed to detect active disease in two patients, resulting in a detection rate of 86.7% (13/15), while [68Ga]Ga-DOTA-TOC and [18F]FDOPA PET successfully identified all patients (15/15, 100%). A total of 203 lesions were identified in the lesion-based analysis. [68Ga]Ga-DOTA-TOC PET demonstrated superior detectability (199/203 lesions, 98.0%), compared to [18F]FDOPA PET (129/203, 63.5%) and [18F]FDG PET (122/203, 60.1%) (p < 0.001). SUVmax was highest for [68Ga]Ga-DOTA-TOC PET (5.5 ± 4.0), followed by [18F]FDG PET (1.8 ± 1.4) and [18F]FDOPA PET (0.6 ± 0.5) (p < 0.001). Organ-based analysis revealed that [68Ga]Ga-DOTA-TOC provides superior detection rates in lymph node (55/57, 96.5%), soft tissue (43/43, 100%), bone and bone marrow (89/89, 100%) metastases. SUVmax was generally higher on [68Ga]Ga-DOTA-TOC PET/CT for both primary lesions and metastases (all p < 0.001), except in the liver. The majority of lesions (170/203, 83.7%) exhibited a Krenning score of 2 or higher. CONCLUSION: The enrichment of somatostatin receptors in neuroblastoma makes [68Ga]Ga-DOTA-TOC PET a highly effective detection tool compared to [18F]FDOPA PET and [18F]FDG PET. A multimodal imaging approach can enhance disease evaluation and guide personalized therapeutic strategies, potentially facilitating radioligand therapy.
引用
- Liu CJ, Ko KY, Lu MY, et al. [68Ga]Ga-DOTA-TOC positron emission tomography outperforms [18F]FDOPA and [18F]FDG PET in pediatric neuroblastoma imaging: a prospective study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40512254. doi:10.1007/s00259-025-07399-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。